You are here: Industry Insights > EW

News List

A Record High! A Review of Groundbreaking New Drugs in China in 2024, with the Number of Innovative Drugs Reaching New Heights! Sophia
January 23, 2025
In 2024, China's pharmaceutical field thrived. NMPA approved 220 new drugs, including 46 Class 1 innovative ones with anti-tumor drugs being the most. New anti-tumor drugs offered hope, and the R&D environment will keep improving.
Ikena Oncology and Inmagene signed a merger deal. The new firm focuses on IMG-007 for atopic dermatitis. Reverse mergers among Chinese pharma firms are rising. Xiaobin
January 23, 2025
Qilu Pharmaceutical applied for marketing of nusinersen injection, becoming the second in China. Nusinersen has a complex history due to high price. SMA treatment has multiple drugs and Chinese firms are making progress, with unmet needs remaining.
New FDA Regulations in the Year 2024 Muhammad Asim Niazi
January 07, 2025
The United States FDA regulates pharma drug products manufactured or marketed in the United States. There are many different functions of the FDA, and one of them is devising new regulations.
Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global Yi
December 20, 2024
On November 18, it was announced that VelaVigo has entered into a global strategic cooperation agreement with Avenzo Therapeutics.
New Pathways for Innovation and Transformation of Local Pharmaceutical Companies Xiaobin
December 20, 2024
INNOVATION announced it will acquire 100% equity in CSPC Baike for up to RMB 7.6 billion, 10% in cash and 90% in shares.
Where Lies the Competitiveness of China's New Drugs for Central Nervous System? Prof. Zhang
October 18, 2024
The Global Challenges and Opportunities of the R&D of New Drugs for Central Nervous System
New Indication Approval for Ribociclib: A Game Changer for CDK4/6 Inhibitors Yefenghong
October 18, 2024
Recently, the FDA officially approved Novartis's ribociclib, in combination with aromatase inhibitors (AI), for the adjuvant treatment of hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC)
Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market PharmaSources
October 14, 2024
Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc. celebrated the opening of its new cutting-edge biopharmaceutical cGMP facility in Bovenau .
NEW OPTURA®PALM® Handheld Contactless Biomass Sensor from Aber Offers Accurate Cell Density Measurement in Seconds Without Sampling Biotech Newswire
August 09, 2024
Aber Instruments (Aber) is delighted to introduce its new OPTURA® PALM® handheld biomass sensor.
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues Biotech Newswire
July 24, 2024
Currax Pharmaceuticals LLC announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union and European Union Economic Areas.